Adma Biologics Inc RPE

RPE von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Adma Biologics Inc

Was macht Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Unternehmen mit rpe ähnlich Adma Biologics Inc

• Transmit Entertainment hat RPE von HKD$1.092M
• Harbour Centre Development hat RPE von HKD$1.092M
• Hong Kong & China Gas Co hat RPE von HKD$1.092M
• China Minsheng hat RPE von HKD$1.093M
• British Land Plc hat RPE von £1.093M
• The British Land Co. Plc hat RPE von £1.093M
• Adma Biologics Inc hat RPE von $1.094M
• United Airlines Inc hat RPE von $1.094M
• Lai Fung hat RPE von HKD$1.094M
• Northeast Electric Development hat RPE von ¥1.095M
• Dine Brands Global Inc hat RPE von $1.095M
• Preferred Apartment Communities Inc hat RPE von $1.095M
• Heliospectra AB hat RPE von kr1.097M